[Osteonecrosis of the jaws and bisphosphonates].
Widely prescribed, bisphosphonates inhibit bone resorption. They are not metabolised and have long half-lives. Two cases of osteonecrosis of the jaws have recently been attributed to bisphosphonates at the University Hospital of Geneva. The recent literature reveals more than a hundred similar cases throughout the world. Bone exposure appears spontaneously or after dental care. Treatment of the osteonecrosis is controversial and cure very difficult. This pathology is usually seen in patients on chemotherapy, steroids and i.v. bisphosphonates, but is sometimes seen with low-dose p.o. bisphosphonates. In view of the strong association between bisphosphonate therapy and osteonecrosis of the jaw, specialists have recommended dental and oral evaluation during bisphosphonate therapy as well as for several years after drug discontinuation.
Junod
A F
AF
Unité de Gerontopharmacologie Clinique, Départment de Réhabilitation et Gériatrie, Hôpital de gériatrie, Thônex. Anne.F.Junod@hcuge.ch
Carrel
J-P
JP
Richter
M
M
Vogt-Ferrier
N
N
D000367:Age Factors; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D007262:Infusions, Intravenous; D007568:Jaw / Q000473:pathology*; D010020:Osteonecrosis / Q000139:chemically induced*; D013256:Steroids / Q000627:therapeutic use
D004164:Diphosphonates; D013256:Steroids